197
Views
0
CrossRef citations to date
0
Altmetric
Real-World Evidence

Real-world clinical outcomes and healthcare costs in patients with Crohn’s disease treated with vedolizumab versus ustekinumab in the United States

, , , , , , , , & show all
Pages 877-885 | Received 13 Jul 2023, Accepted 29 Feb 2024, Published online: 08 Apr 2024

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.